Performance of ARWR Arrowhead Pharmaceuticals | -43.9% in 12m
Compare ARWR with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Arrowhead Pharmaceuticals with its related Sector/Index XBI
Performance Duell ARWR vs XBI
| TimeFrame | ARWR | XBI |
|---|---|---|
| 1 Day | -10.7% | -0.94% |
| 1 Week | -12.2% | -2.69% |
| 1 Month | -10.6% | -0.01% |
| 3 Months | -31.6% | -5.33% |
| 6 Months | -15.0% | 31.03% |
| 12 Months | -43.9% | 3.19% |
| YTD | -28.8% | -2.32% |
| Rel. Perf. 1m | -0.67 | |
| Rel. Perf. 3m | -2.59 | |
| Rel. Perf. 6m | -3.82 | |
| Rel. Perf. 12m | -5.71 |
Is Arrowhead Pharmaceuticals a good stock to buy?
No, based on ValueRay Fundamental Analyses, Arrowhead Pharmaceuticals (NASDAQ:ARWR) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -85.03 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 18.87. This means that ARWR is currently overvalued and has a potential downside of -14.54% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARWR as of May 2024 is 18.87. This means that ARWR is currently overvalued and has a potential downside of -14.54% (Sold with Premium).
Is ARWR a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 4
- Sell: 0
- Strong Sell: 0
Values above 0%: ARWR is performing better - Values below 0%: ARWR is underperforming
Compare ARWR with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -13.07% | -12.57% | -34.15% | -72.23% |
| US NASDAQ 100 | QQQ | -12.65% | -11.47% | -32.62% | -80.76% |
| US Dow Jones Industrial 30 | DIA | -13.97% | -14.69% | -31.08% | -64.75% |
| German DAX 40 | DBXD | -15.35% | -15.00% | -36.92% | -61.31% |
| UK FTSE 100 | ISFU | -13.52% | -17.00% | -32.91% | -57.21% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -12.00% | -17.31% | -17.63% | -35.36% |
| Hongkong Hang Seng | HSI | -14.65% | -25.45% | -18.89% | -35.04% |
| Japan Nikkei 225 | EXX7 | -9.64% | -5.66% | -27.81% | -57.41% |
| India NIFTY 50 | INDA | -10.33% | -10.03% | -30.63% | -68.41% |
| Brasil Bovespa | EWZ | -10.01% | -11.70% | -16.22% | -56.40% |
ARWR Arrowhead Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -12.84% | -11.18% | -35.31% | -82.10% |
| Consumer Discretionary | XLY | -11.29% | -11.17% | -25.29% | -65.26% |
| Consumer Staples | XLP | -14.48% | -16.39% | -28.86% | -47.44% |
| Energy | XLE | -12.81% | -8.22% | -28.65% | -67.48% |
| Financial | XLF | -14.09% | -15.03% | -39.59% | -77.32% |
| Health Care | XLV | -13.79% | -13.98% | -28.96% | -54.26% |
| Industrial | XLI | -13.59% | -12.87% | -38.48% | -73.61% |
| Materials | XLB | -14.21% | -12.75% | -35.13% | -63.86% |
| Real Estate | XLRE | -14.35% | -12.14% | -27.80% | -49.43% |
| Technology | XLK | -12.54% | -10.67% | -30.59% | -81.12% |
| Utilities | XLU | -15.89% | -21.62% | -36.68% | -50.65% |
| Aerospace & Defense | XAR | -12.56% | -16.92% | -31.29% | -70.82% |
| Biotech | XBI | -9.55% | -10.60% | -46.01% | -47.04% |
| Homebuilder | XHB | -12.85% | -13.75% | -54.69% | -96.99% |
| Retail | XRT | -12.37% | -14.09% | -40.99% | -68.06% |
Does Arrowhead Pharmaceuticals outperform its market, is ARWR a Sector Leader?
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -43.85%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months ARWR made -31.56%, while XBI made -5.33%.
No, over the last 12 months Arrowhead Pharmaceuticals (ARWR) made -43.85%, while its related Sector, the SPDR S&P Biotech (XBI) made 3.19%.
Over the last 3 months ARWR made -31.56%, while XBI made -5.33%.
| Period | ARWR | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -10.61% | -0.01% | 1.96% |
| 3 Months | -31.56% | -5.33% | 4.29% |
| 12 Months | -43.85% | 3.19% | 28.38% |